Post-marketing drug surveillance for adverse drug events (ADEs) has typically relied on
spontaneous reporting. Recently, regulatory agencies have turned their attention to more …

Importance Current approaches to classify the hepatotoxic potential of medications are
based on cumulative case reports of acute liver injury (ALI), which do not consider the size of …

Pre-existing liver disease in patients with invasive fungal infections further complicates their
management. Altered pharmacokinetics and tolerance issues of antifungal drugs are …

Background & Aims It is not clear whether evidence-based recommendations for inpatient
care of patients with cirrhosis are implemented widely or are effective in the community. We …

Background & Aims Medications are a major cause of acute liver failure (ALF) in the United
States, but no population-based studies have evaluated the incidence of ALF from drug …

Objective The combination of phenomic data from electronic health records (EHR) and
clinical data repositories with dense biological data has enabled genomic and …

Objective To assess the risk of liver injury hospitalisation in patients with atrial fibrillation
(AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine …

Background Reports on associations between azole antifungal medications and acute liver
injury are inconsistent and have not been based on liver-related laboratory tests. We …

Background: Patients with decompensated cirrhosis have high rates of morbidity and
mortality and frequently require hospital admission. Few studies have examined early …

Background Hepatotoxicity may be a concern when prescribing antidepressants.
Nevertheless, this risk remains poorly understood for serotonin and noradrenaline reuptake …